2020
Association of pre-existing mental illness with all-cause and cancer-specific mortality among Medicare beneficiaries with pancreatic cancer
Paredes AZ, Hyer JM, Tsilimigras DI, Palmer E, Lustberg MB, Dillhoff ME, Cloyd JM, Tsung A, Ejaz A, Wells-Di Gregorio S, Pawlik TM. Association of pre-existing mental illness with all-cause and cancer-specific mortality among Medicare beneficiaries with pancreatic cancer. Hepato Pancreato Biliary 2020, 23: 451-458. PMID: 32843275, DOI: 10.1016/j.hpb.2020.08.002.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedHumansMedicareMental DisordersPancreatic NeoplasmsRetrospective StudiesUnited StatesConceptsCancer-specific mortalityLong-term outcomesPancreatic cancerMental illnessPre-existing mental illnessSchizophrenic disordersHigh riskMedicare beneficiariesCancer-directed surgerySEER-Medicare databasePre-existing historyAnxiety/depressionEarly-stage cancerCause mortalityMultivariable analysisPancreatic adenocarcinomaStage cancerPsychotic disordersPatientsBipolar disorderIllnessCancerMortalityDisordersDepression
2015
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary
Mikhail S, Lustberg M, Ruppert A, Mortazavi A, Monk P, Kleiber B, Villalona-Calero M, Bekaii-Saab T. Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. Cancer Chemotherapy And Pharmacology 2015, 76: 1005-1012. PMID: 26416564, DOI: 10.1007/s00280-015-2877-6.Peer-Reviewed Original ResearchMeSH KeywordsActivation, MetabolicAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCapecitabineCarboplatinDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleEnzyme InductionEsophageal NeoplasmsFatigueFemaleGene Expression Regulation, NeoplasticHematologic DiseasesHumansKaplan-Meier EstimateMaleMaximum Tolerated DoseMiddle AgedNeoplasmsNeoplasms, Unknown PrimaryPaclitaxelPancreatic NeoplasmsProdrugsThymidine PhosphorylaseTreatment OutcomeUp-RegulationYoung AdultConceptsAdvanced solid tumorsII studyUnknown primaryDay 1Phase I/II studySolid tumorsPhase IPhase II patientsAntitumor activityObjective response ratePhase II dosePhase II studyMaximal tolerable doseSynergistic antitumor activityCessation of fundingCapecitabine 750Paclitaxel 60Disease stabilizationAcceptable tolerabilityAdvanced adenocarcinomaPartial responseCarboplatin AUCII patientsTolerable dosePatients
2010
Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma
Lustberg M, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg M, Villalona-Calero M. Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma. Journal Of Thoracic Oncology 2010, 5: 713-718. PMID: 20354452, PMCID: PMC3641556, DOI: 10.1097/jto.0b013e3181d7776d.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsCamptothecinCarcinoma, Squamous CellEsophageal NeoplasmsEsophagogastric JunctionFemaleHumansIrinotecanLiver NeoplasmsLung NeoplasmsLymphatic MetastasisMaleMiddle AgedMitomycinNeoplasm StagingStomach NeoplasmsSurvival RateTreatment OutcomeConceptsMitomycin CDay 1Day 2Phase II Randomized StudyComplete pathologic responsePhase II evaluationGastroesophageal junction adenocarcinomaUnresectable esophagealEvaluable patientsGastroesophageal adenocarcinomaJunction adenocarcinomaPathologic responseRandomized studyArm AGastroesophageal junctionFuture trialsEsophageal cancerII evaluationSevere toxicityPatientsIrinotecanResponse ratePhase IAdenocarcinomaTopoisomerase 1